Abstract
In light of the poor prognosis for ovarian cancer patients, the research continues for innovative and efficacious treatment modalities. Along with surgical and chemotherapeutic regimens, gene therapy has emerged as one of the leading contenders in the treatment armamentarium. Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone. However, the biological function of Hepsin expression remains unclear. Apoptotic cell was increasingly common among higher proportions of Hepsin transfectants. We discovered that first-time stable transfectants of Hepsin significantly inhibited cell growth in the monolayer, anchorage-independent cell growth in the soft agar in vitro, and tumorigenicity in vivo in ovarian cancer cell lines. These results demonstrated that Hepsin has a potential therapeutic effect that inhibits through up-regulation of p53-dependent apoptosis and caspase-3, -6, and -7 activations. Our findings in this study identify Hepsin as a target for new approaches in ovarian cancer treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 393-398 |
| Number of pages | 6 |
| Journal | International Journal of Oncology |
| Volume | 28 |
| Issue number | 2 |
| Publication status | Published - Feb 2006 |
Fingerprint
Keywords
- Caspase
- Hepsin
- Ovarian cancer
- p53-dependent apoptotic pathway
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines. / Nakamura, Keiichiro; Nasu, Yasutomo; Hongo, Atsushi; Matsuo, Tamaki; Kodama, Junichi; Ebara, Shin; Nagai, Atsushi; Abrzua, Fernando; Kumon, Hiromi; Hiramatsu, Yuji.
In: International Journal of Oncology, Vol. 28, No. 2, 02.2006, p. 393-398.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines
AU - Nakamura, Keiichiro
AU - Nasu, Yasutomo
AU - Hongo, Atsushi
AU - Matsuo, Tamaki
AU - Kodama, Junichi
AU - Ebara, Shin
AU - Nagai, Atsushi
AU - Abrzua, Fernando
AU - Kumon, Hiromi
AU - Hiramatsu, Yuji
PY - 2006/2
Y1 - 2006/2
N2 - In light of the poor prognosis for ovarian cancer patients, the research continues for innovative and efficacious treatment modalities. Along with surgical and chemotherapeutic regimens, gene therapy has emerged as one of the leading contenders in the treatment armamentarium. Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone. However, the biological function of Hepsin expression remains unclear. Apoptotic cell was increasingly common among higher proportions of Hepsin transfectants. We discovered that first-time stable transfectants of Hepsin significantly inhibited cell growth in the monolayer, anchorage-independent cell growth in the soft agar in vitro, and tumorigenicity in vivo in ovarian cancer cell lines. These results demonstrated that Hepsin has a potential therapeutic effect that inhibits through up-regulation of p53-dependent apoptosis and caspase-3, -6, and -7 activations. Our findings in this study identify Hepsin as a target for new approaches in ovarian cancer treatment.
AB - In light of the poor prognosis for ovarian cancer patients, the research continues for innovative and efficacious treatment modalities. Along with surgical and chemotherapeutic regimens, gene therapy has emerged as one of the leading contenders in the treatment armamentarium. Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone. However, the biological function of Hepsin expression remains unclear. Apoptotic cell was increasingly common among higher proportions of Hepsin transfectants. We discovered that first-time stable transfectants of Hepsin significantly inhibited cell growth in the monolayer, anchorage-independent cell growth in the soft agar in vitro, and tumorigenicity in vivo in ovarian cancer cell lines. These results demonstrated that Hepsin has a potential therapeutic effect that inhibits through up-regulation of p53-dependent apoptosis and caspase-3, -6, and -7 activations. Our findings in this study identify Hepsin as a target for new approaches in ovarian cancer treatment.
KW - Caspase
KW - Hepsin
KW - Ovarian cancer
KW - p53-dependent apoptotic pathway
UR - http://www.scopus.com/inward/record.url?scp=39049181069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39049181069&partnerID=8YFLogxK
M3 - Article
C2 - 16391794
AN - SCOPUS:39049181069
VL - 28
SP - 393
EP - 398
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 2
ER -